Avidity Biosciences, Inc. (NASDAQ:RNA) Cantor Global Healthcare Conference 2025 September 3, 2025 10:20 AM EDT
Company Participants
Sarah Boyce – President, CEO & Director
Steven Hughes – Chief Medical Officer
Conference Call Participants
Eric Schmidt – Cantor Fitzgerald & Co., Research Division
Presentation
Eric Schmidt
Research Analyst
Okay. Good morning once again, everyone. My name is Eric Schmidt. I’m one of the Cantor analysts. I am delighted to host our next session with Avidity Biosciences. I’m also delighted to welcome 2 of the company’s senior executives. We have with us today Sarah Boyce, who’s the company’s President and CEO; and also Steve Hughes, the company’s Chief Medical Officer. I think somewhere in the audience, Kat Lange may be here as well. She’s the Chief Business Officer. There she is.
So pretty much the whole team and lots and lots to cover. An exciting period of time for Avidity coming off what’s been a tremendous run in terms of executing along 3 muscle disease programs.
Question-and-Answer Session
Eric Schmidt
Cantor Fitzgerald & Co., Research Division
So Sarah, maybe you could just orient all of us to the highlights of the company right now.
Sarah Boyce
President, CEO & Director
Yes. So maybe I’ll start with vision because that really is our guiding star. We’re looking to do 2 things: revolutionize the RNA space and make a profound impact in people’s lives. It’s a very bold vision, we laid it out 6 years ago. This is our guiding star, and that sets us to where we are today, where we have 3 programs in the late stages of development.
The first being del-zota for boys and young men amenable to exon 44 skipping. And we are on track and on schedule to file our first BLA as a company at the end of
#Avidity #Biosciences #RNA #Cantor #Global #Healthcare #Conference #Transcript